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Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Improvement of treatment efficacy and
decreased side effects through tumor-targeted drug delivery would be desirable. By panning with a phage-displayed cyclic
random peptide library we selected a peptide with strong affinity for RMS in vitro and in vivo. The peptide minimal binding
motif Arg-X-(Arg/Lys)(Arg/Lys) identified by alanine-scan, suggested the target receptor to be a proprotein convertase (PC).
Expression profiling of all PCs in RMS biopsies and cell lines revealed consistent high expression levels for the membrane-
bound furin and PC7. Direct binding of RMS-P3 peptide to furin was demonstrated by affinity chromatography and
supported by activity and colocalization studies. Treatment of RMS in mice with doxorubicin coupled to the targeting
peptide resulted in a two-fold increase in therapeutic efficacy compared to doxorubicin treatment alone. Our findings
indicate surface-furin binding as novel mechanism for therapeutic cell penetration which needs to be further investigated.
Furthermore, this work demonstrates that specific targeting of membrane-bound furin in tumors is possible for and
suggests that RMS and other tumors might benefit from proprotein convertases targeted drug delivery.
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Introduction
Rhabdomyosarcoma (RMS), the most common soft tissue
sarcoma in children, is thought to develop through disruption of
muscle differentiation and can therefore arise anywhere in the body
[1]. Treatment response and prognosis vary widely depending on
location and histological RMS subtype.
Two main distinct histological subgroups exist with prognostic
significance: embryonal rhabdomyosarcoma (eRMS) found in
60% and alveolar rhabdomyosarcoma (aRMS) found in 20% of
patients. The latter represents the more aggressive subtype with
the poorest prognosis at diagnosis [2]. The exact determination of
the tumor mass and spread is important for tumor staging and
appropriate therapy design consisting of the combination of
surgery and chemotherapy. Since relapsing RMS are usually
refractory to standard chemotherapy, the use of more aggressive
therapies is needed with long lasting side-effects which affect
normal child development.
Current therapies for RMS could be improved by targeting the
tumor either by tumor specific compounds, or by delivering
conventional drugs specifically to the tumor. No specific targeting
approach is so far available neither for RMS nor any other
pediatric embryonal tumor. Most work has focused on the
development of monoclonal or single chain antibodies to tumor-
associated antigens, coupled to an anticancer agent [3,4,5].
Unfortunately, such therapies showed limited efficacy in solid
tumors such as RMS due to poor tumor penetration [6]. To
overcome these drawbacks, small peptide-based compounds have
been considered as carrier molecules to selectively deliver
compounds to tumor specific receptors [7,8]. Many promising
lead compounds are being identified through screenings of large
biological and synthetic peptide libraries [9], such as phage
displayed random peptide libraries,[10,11].
Proprotein convertases (PC) are a family of subtilisin-like serine
proteases. They play a crucial role in the processing of various
protein precursors ranging from hormones, growth factors,
adhesion molecules, extracellular proteins to viral-envelop glyco-
proteins and bacterial exotoxins [12,13]. Seven out of nine family
members generate active proteins through post-translational
endoproteolysis of precursors at the specific recognition sequence
Arg-X(Arg/Lys)(Arg/Lys), namely furin, PC1/3, PC2, PC4,
PACE4, PC5/6 A and B and PC7, whereof only furin, PC5B
and PC7 are transmembrane proteins. They cycle between the
surface and the trans Golgi network while processing their
substrates [14,15]. Endogenous expression of furin is detectable
in normal tissue, while elevated furin expression is associated with
several diseases including cancer [16,17]. In particular, furin
overexpression has been linked to aggressive metastatic tumors
[18] presumably by activating cancer-promoting factors which
include vascular endothelial growth factors (VEGF-C and D)
[19,20], transforming growth factor b (TGF-b) [21], insulin-like
growth factor 1 receptor (IGF-R1) [22], bone morphogenic
protein 4 (BMP-4) [23] membrane type 1 matrix metalloprotei-
nase (MMP-1) [24] and several adamalysin metalloproteinases
[25] as well as integrins [26]; or by inactivating tumor suppressors
like Semaphorin-3B [27]. Inhibition of furin decreases tumor
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tumor models indicate a more complex contribution of PCs to
tumorigenesis [31,32] Thus, although the dual role of PCs in
tumorigenesis has to be further investigated, PCs represent a
promising target to decrease or even prevent the activation of
cancer-promoting factors [33].
We have previously identified two RMS targeting peptides
through an in vitro screening of a phage-displayed random peptide
library on RMS cell lines [34]. In this study, we improved the
screening approach by combining in vitro and in vivo panning, and
tested the identified RMS targeting peptide for selective drug
delivery to RMS.
Results
Screening for phage-displayed peptides binding to RMS
cells
To identify peptides that bind specifically to RMS, we
performed in vitro and in vivo phage screening. First, a phage-
displayed random cyclic peptide library was depleted of phage
binding to normal cells by negative selection on either myoblasts
(panning I) or fibroblasts (panning II). The precleared libraries
were used in two parallel screenings on cultured RD cells for five
rounds of selection. These yielded a phage pool that bound to RD
cells 1200-fold for panning I and 900-fold for panning II over non-
recombinant T7 (Supp. Fig. S1A and S1B). Subsequently, both in
vitro selections were pooled and subjected to an in vivo screening on
RMS xenografts. After two rounds of in vivo selection, phage-
binding to tumors increased to 50-fold over non-recombinant T7
(Supp. Fig. S1C). To identify peptides displayed by the phages, 40
phages from each in vitro screening and 30 phages from the
enriched population in vivo were randomly picked and sequenced.
Analysis of the sequences revealed the recurrence of six phages
(Table 1). Alignment of the peptide sequences indicated frequent
presence of arginines and lysines, suggesting the importance of
these basic residues. Four phages had the amino acid sequence
Arg-X-Arg-Arg (RXRR), whereas X stands for a neutral, polar
amino acid. Two phage clones (RMS-P3 and RMS-P6) had the
sequence Arg-Thr-Lys-Lys (RTKK). RMS-P6 was the most
abundant phage selected both in vitro as well as in vivo (43% and
27%, respectively).
Selection and validation of RMS binding peptides
The specificity of the enriched phages was tested in binding
assays to RMS and normal cells individually (Fig. 1A). For each
phage, binding was significantly better on cancer cells than on
normal cells, except for control phage Pctrl. The most abundant
phage, PMS-P6 (CMGTTNTRTKKC), bound 1270-fold to RD,
230-fold to Rh4 and 120-fold to Rh30 cells compared to the non-
recombinant phage T7. Interestingly, phage RMS-P3
(CMGTINTRTKKC), differing from RMS-P6 only in one amino
acid, bound 4 to 10 times better than phage RMS-P6 to all RMS
cells tested, suggesting an important role for the isoleucine for
binding efficiency. Phage RMS-Pctrl (CSPNNTRRPNKC) arose
spontaneously during the in vitro screening and had a similar
sequence to RMS-P6 and RMS-P3 but showed no binding to
tumor cells and was therefore used as negative control. Phages
bound to the different RMS histosubtypes, alveolar and embry-
onal, equally well. Based on these results, phage RMS-P3 and
RMS-P6 were further tested for their ability to bind to RMS
tumors in vivo in mice bearing either eRMS (RD cells, Fig. 1B) or
aRMS (Rh4 cells, Supp. Fig. S1D). Both phages bound
significantly better to tumors than to any other organ (calculated
with One-way ANOVA and Tukey-Kramer HSD). Tumor
binding in vivo was up to 50-fold lower than in vitro. Enrichment
of phages in vivo is usually much lower than in vitro. This is partly
due to a higher background binding and to higher complexity of
tissues, but it also might indicate that the target is less accessible or
expressed at lower levels in vivo compared to cultured tumor cells.
RMS-P3 revealed the best tumor/muscle ratio (24-fold) in both
xenografted RMS histosubtypes and was therefore selected for
further studies. Therefore, RMS-P3 cognate peptide was synthe-
sized to test its ability to compete with phage RMS-P3 for the
binding to RD cells in vitro. Constant amounts of phage RMS-P3
were incubated with increasing concentrations of peptide RMS-P3
or control peptide RMS-Pctrl (Fig. 1C). We observed a significant
correlation between increasing peptide concentrations and de-
creasing phage binding. Half-maximal inhibition (IC50) of phage
binding by the synthetic peptide was approximately at 100 nM
and the highest concentration tested (10 mM) decreased phage
binding to 7.5%. Control peptide RMS-Pctrl had no effect on
phage RMS-P3 binding. We therefore conclude that RMS-P3
phage binding to RD cells is mediated by the displayed peptide
and the synthetic peptide retains its binding specificity. The
binding of phage RMS-P3 was further investigated on different
cancer and normal cells (Supp. Fig. S1E). This experiment
revealed a significant binding of RMS-P3 also to breast carcinoma,
glioblastoma and melanoma cells compared to myoblasts and
fibroblasts (One-way ANOVA with Tukey Kramer HSD test,
p,0.05), suggesting that the potential target is overexpressed on
different tumor cell lines.
RMS-P3 peptide localizes on the cell surface and Golgi
structures of tumor cells in vitro and in vivo
To characterize the binding of peptide RMS-P3 on cultured
cells, the corresponding fluorescein-conjugated peptide (FITC-
RMS-P3) was incubated with myoblasts, fibroblasts, RMS or
Table 1. Alignment of phage displayed peptide sequences selected from RMS cells in vitro and in vivo.
Phage name Displayed peptide sequence
A Frequency in both selections in vitro Frequency in selection in vivo
RMS-P6 CMGTTNTRTKKC 34/80 43% 6/30 27%
RMS-P3 CMGTINTRTKKC 14/80 18% 6/30 17%
RMS-P7 CGTGSRARRSC 7/80 9% 3/30 10%
RMS-P10 CLTGRQRRSSQC 4/80 5% 2/30 7%
RMS-P9 CSGPNVRSRRC 3/80 4% 2/30 7%
RMS-P8 CRTGRQRRSSEC 3/80 4% 2/30 7%
APhage-displayed consensus motifs are shown in bold letters.
doi:10.1371/journal.pone.0010445.t001
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PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10445Figure 1. Validation of selected phages binding on RMS cells in vivo and in vitro. (A) Quantification of binding of single phage clones to
different cell lines. Six phages selected from in vitro and in vivo screenings were validated individually in binding assays to three RMS cell lines
(embryonal RMS: RD; alveolar RMS: Rh30 and Rh4) as well as to normal myoblasts (SkMC-c) and fibroblast cells (MRC-5). Phage clones are ordered
according to the frequency of occurrence. Binding was calculated over non-recombinant T7, depicted are mean values 6 SD of three independent
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cancer cells, but not on normal cells (Fig. 2A). Interestingly, the
fluorescence did not exclusively localize on the cell surface, but
seemed to accumulate inside the cells. To address the subcellular
localization of RMS-P3 in RD cells, we compared the pattern of
the fluorescent peptide with that of giantin, a marker for the Golgi
compartment (Fig. 2B). A clear colocalization of FITC-RMS-P3
and the giantin staining was visible in reticular and perinuclear
distribution, indicating that FITC-RMS-P3 binds both to the cell
surface as well as to Golgi-associated structures. Confocal
microscopy confirmed FITC-RMS-P3 internalization in RD cells
(Supp. Fig. S2). Binding of FITC-RMS-P3 to RMS tumors was
further investigated in vivo in RD xenografts. The labeled peptide
was specifically detected within endothelial and peri-endothelial
tumor cells whereas control organs like muscle and brain remained
unaffected. Only kidneys showed a low peptide uptake (Fig. 2C).
However, the control peptide FITC-RMS-Pctrl - which did not
accumulate in the tumor - showed a strong kidney uptake (Fig 2D).
experiments. (B) RMS-P3 and RMS-P6 phage distribution in RD mouse xenografts. Homing of phages to tumor was compared to control organs.
Binding was normalized over phage T7 and tissue weight. Mean values 6 SD of four independent experiments are shown. Numerical values for tumor
to organ ratios are indicated above the bars. (C) Validation of RMS-P3 peptide sequence by competition of phage binding. 10
6 RD cells were
incubated for 30 min with increasing concentrations of RMS-P3 peptide (CMGTINTRTKKC) or control peptide (CSPNNTRRPNKC). Then, phages (10
9
pfu) were added for 1 h. Phage binding was normalized over non-recombinant T7. Data are presented as percentage of maximal phage binding
obtained in the absence of synthetic peptide. Error bars indicate mean 6 SD from three independent experiments. Binding of phage RMS-P3
decreases significantly with increasing concentrations of synthetic peptide RMP-P3 (least-squares regression, N=18, r
2=0.889, b=217.5, p,0.0001),
but not for control peptide (N=18, r
2=0.0002, b=0.055, p=0.959).
doi:10.1371/journal.pone.0010445.g001
Figure 2. FITC-labeled RMS-P3 binding in vitro and distribution in vivo. (A) Visualization of FITC-RMS-P3 peptide binding in normal and
cancer cells in vitro. Cultured myoblasts (SkMC-c), fibroblasts (MRC-5), RMS cells (RD) and breast carcinoma cells (MDA-MB 231) were incubated with
100 nM FITC-RMS-P3 peptide for 1 h at 37uC. Fluorescence microscopy of fixed cells is shown. (B) Living RD cells were incubated with FITC-RMS-P3
peptide, subsequently fixed and stained with giantin (red). Colocalization is shown in the merged picture by yellow. Blue staining (DAPI) indicates the
nuclei. Magnifications: 40x, scale bars: 20 mm. (C) Distribution of FITC-RMS-P3 and control peptide FITC-RMS-Pctrl in mice xenografts of RD cells. FITC-
RMS-P3 or control FITC-RMS-Pctrl peptide were injected i.v. and after 10 minutes of circulation, mice were perfused and tumor and control organs
were collected. Cryosections were double-labeled with mouse endothelial vessels markers CD31 and MECA-32 (red). Nuclear staining by DAPI is
shown in blue. Magnifications: 40x, scale bars: 20 mm.
doi:10.1371/journal.pone.0010445.g002
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shown by confocal microscopy (Supp. Fig. S2). In conclusion,
FITC-RMS-P3 shows preferential accumulation in RMS tumors,
confirming the tumor specificity in vivo.
Identification of the RMS-P3 binding motif
To identify the minimal binding motif necessary for binding of
RMS-P3, new phage clones were synthesized whereby each amino
acid was singularly replaced by alanine (Ala-scan). All phage
mutants were tested individually for their binding to RD cells
(Fig. 3A). Comparing RMS-P3 mutants to RMS-P3, a dramatic
decrease in binding could be observed when Arg at position 7 (60-
fold decrease) or both Lys (57-fold decrease at position 9, 56-fold at
position 10) were exchanged. Replacing Ile at position 4 had a
minor but significant effect and resulted in 10-fold decreased
binding. When all basic amino acids at positions 7, 9 and 10 were
replaced by Ala (RMS-P3/AA), binding was almost completely
abolished (70-fold decrease). To test whether the presence of any
basic amino acid is sufficient for binding, both Lys were replaced
by Arg (RMS-P3/RR). Results revealed no significant difference
Figure 3. Identification of the receptor for RMS-P3. (A) Alanine-scan of the RMS-P3 sequence. RMS-P3 was mutated by replacing each amino
acid residue with alanine (codon GCT). All phage mutants were tested individually for binding to RD cells in vitro. Mutated residues are indicated in
bold. Phage binding was quantified over non-recombinant T7 and compared to the binding of wild type phage RMS-P3. Depicted are mean values 6
SD of three independent experiments. Phage RMS-P3/RR shows no different binding to RD cells than phage RMS-P3, but both are significantly
different from all other alanine mutants (One-way ANOVA, with Tukey Karmer HSD test, p,0.05). Bars not connected by same signs are significantly
different from each other. (B) FITC-RMS-P3/RR and FITC-RMS-P3/AA distribution in RD xenograft mice. After tail vein injection of both FITC-RMS-P3/RR
or control peptide RMS-P3/AA and circulation of 10 min, mice were perfused, tumors and control organs were dissected and FITC-peptide
distribution (green) was evaluated in cryosections under fluorescence microscopy. Blood endothelial stainings (CD31 and MECA32) are shown in red,
nuclear staining in blue (DAPI). Magnification: 20x, scale bar 50 mm. (C) Expression of proprotein convertases (PCs) measured by microarray profiling
of 9 RMS cell lines and 30 RMS biopsy samples. Expression of PCs recognizing the cleavage site R(X)(R/K)(R/K) were considered. Each cell line or biopsy
is represented by one data point. (D) Furin expression in different cell lines. Normal myoblasts (SkMC-c), fibroblasts (MRC-5), RMS cell lines (RD, Rh4,
Rh30), furin-deficient colorectal carcinoma cells (LoVo) and furin-positive breast carcinoma cells (MBA-MB 231) were tested for furin expression by
qRT-PCR (upper graph). SkmC-c and MRC-5 show both significantly lower RNA levels than any tumor cells (One-way ANOVA, Tukey Kramer HSD tests,
p,0.05), but similar values to Lovo negative control (not significant). mRNA expression levels are depicted relative to the sample with the highest
expression after normalization to GAPDH. Western blot (lower panels). Immature membrane-bound furin was detected at 103 kD, mature furin at 97
kD. PCNA was used as loading control.
doi:10.1371/journal.pone.0010445.g003
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indicating that any polar basic residues are sufficient for binding,
but both are significantly different from all other alanine mutants
(One-way ANOVA and Tukey Karmer HSD test, p,0.05). Since
exchange of Lys to Arg decreases the hydrophilic character of the
peptide and therefore lowers the kidney uptake in vivo, we tested
the distribution of fluorescently-labeled peptide RMS-P3/RR in
vivo and compared it to the Ala mutant RMS-P3/AA as negative
control (Fig. 3B). Accumulation of FITC-RMS-P3/RR could be
observed in RMS tumors, but not in control organs (muscle and
kidney); the Ala mutant RMS-P3/AA did not accumulate in the
tumor, but was found in the kidneys. These results confirm the
specificity in vivo, and allowed us to continue our investigations
with the peptide sequence RMS-P3/RR.
Identification of proprotein convertases as candidate
receptor
The minimal binding motif allowed a database search for
proteins containing the sequence RX(R/K)(R/K) to deduce
hypothetical target receptor(s). Indeed, this consensus sequence
could be found in the premature, inactive proform of several
proteins, which are processed by serine endoproteases, namely
proprotein convertases (PCs). This led us to hypothesize that one
of the seven PCs cleaving at the recognition site RX(R/K)(R/K)
might be the binding target of RMS-P3/RR.
Supporting this notion, mRNA expression levels of all PCs with
the recognition site RX(R/K)(R/K) were evaluated in 9 RMS cell
lines and 30 RMS biopsy samples using Affymetrix gene
expression profiles (Fig. 3C). In all tested cell lines and biopsies,
levels of Furin and PC7 were significantly higher than other PCs
(One-way ANOVA, Tukey Kramer HSD tests, p,0.05; Fig. 3C).
Hence, either furin or PC7 were further considered as potential
targets for RMS-P3/RR binding. Since furin has been linked to
tumorigenesis before [18,35], we concentrated our effort on this
enzyme. Expression of furin was investigated at mRNA and
protein level in myoblasts, fibroblasts and RMS cells. MDA-MB
231 [19] and LoVo [36,37] cells were used as positive and negative
controls, respectively. Furin expression was detected by qRT-PCR
in all RMS cell lines at high levels, while myoblasts and fibroblasts
showed low levels of furin transcripts comparable to the cell line
LoVo (Fig. 3D, upper panel). Western blot detected expression of
membrane-bound forms of furin (immature profurin at 103 kD,
mature furin at 97kD) in RD, Rh4, Rh30 and MDA-MB 231 cells
(Fig. 3D, lower panel). These results confirm high expression of
furin in RMS cells supporting the hypothesis that furin might be
the receptor for RMS-P3/RR binding.
RMS-P3/RR binds to furin in vitro
To provide direct evidence for binding of RMS-P3/RR to furin,
we reasoned that furin-overexpression should result in increased
phage RMS-P3/RR binding. Fibroblasts, expressing low levels of
furin, were stably transfected with furin cDNA (MRC-5-FUR).
Expression of immature and mature forms of furin was confirmed
by Western blotting (Fig. 4A, lower panel), whereby the immature
form was predominant. Phage RMS-P3/RR did bind significantly
better to MRC-5-FUR than to MRC-5 or MRC-5-EV (pairwise
comparisons with students t-tests: MRC-5-FUR vs. MRC-5:
p=0.0010, MRC-5-FUR vs. MRC-5-EV: p=0.0008; Fig. 4A,
upper panel). To confirm these results, untransfected and furin-
transfected fibroblasts were incubated with FITC-RMS-P3/RR
and furin expression was analyzed by immunofluorescence. MRC-
5-FUR cells showed a strong peptide binding in contrast to
untransfected cells. Moreover, a clear colocalization of furin and
FITC-RMS-P3/RR was observed (Fig 4B).
On the other hand, inhibition of furin maturation should lead
to a decreased binding of RMS-P3/RR. RD cells were stably
transfected with a1-antitrypsin Portland (a1-PDX), a serpin,
which inhibits irreversibly furin activity [38], and named RD-
PDX. This led to the accumulation of unprocessed profurin, as
indicated by the increased intensity of the 103kD band (Fig. 4C,
lower panel). Phage RMS-P3/RR bound 2.5-fold less to RD-
PDX cells as compared to empty-vector transfected RD cells
(pairwise student’s t-tests: RD-PDX vs. RD p=0.0002, RD-
PDX vs. RD-EV p=0.0004 Fig. 4C, upper panel). This was
further confirmed in competition experiments between the
peptide-based irreversible inhibitor Dec-RVKR-cmk and phage
RMS-P3/RR on RD cells (Fig. 4D). Increasing concentrations
of Dec-RVKR-cmk resulted in decreased phage binding to RD
cells. At 1 mM Dec-RVKR-cmk phage RMS-P3/RR binding
was only half-maximal, whereas the unspecific binding of
control phage RMS-P3/AA remained unaffected. These
findings suggest that Dec-RVKR-cmk and phage RMS-P3/
R Rh a v et h es a m eb i n d i n gs i t e .
To further demonstrate a direct interaction between furin and
the synthetic peptide RMS-P3/RR, the peptide was coupled
covalently to an NHS-activated sepharose column. Furin-
transfected RD cells (RD-FUR) were lysed and the membrane
fraction was incubated with the RMS-P3/RR-column. Un-
bound proteins were removed and bound proteins were eluted
competitively with a concentrated RMS-P3/RR peptide solu-
tion. The washes from the column prior to specific elution
showed no detectable furin. However, competitive eluates
contained detectable amounts of membrane-bound furin
(97kDa), indicating that the peptide can specifically dissociate
furin from the column (Fig. 5A) which was not the case for the
control peptide RMS-P3/AA. 5B). By incubation of the RMS-
P3/RR column with recombinant human furin without
membrane-domain (81 kD) and competitive elution with the
peptide as above, Western blot analysis of the different fractions
detected a furin band in the specific eluate (Fig. 5A). In contrast,
a control RMS-P3/AA-column did not bind recombinant furin
( F i g .5 B ) .T h e s er e s u l t ss t r o n gly suggest that RMS-P3/RR
peptide binds to mature furin, regardless whether it is in its
membrane-bound or soluble form.
To test whether RMS-P3/RR can inhibit furin activity, we
monitored the activity of furin with a fluorogenic substrate in the
presence of increasing concentrations of RMS-P3/RR (Fig. 5C).
Indeed, a concentration dependent decrease of furin activity was
observed, and at a concentration of 100 mM RMS-P3/RR did
reduce furin activity to 14% of the control. Slopes of all RMS-P3/
RR peptide concentrations of at least 50 mM are significantly
different from corresponding RMS-P3/AA peptide concentra-
tion and control (One-way ANCOVA with interaction effect
time*peptide samples, 50 mM, 75 mM and 100 mM RMS-P3/RR
peptide: p,0.0001; for 10 mM p=0.241).
Taken together all these results demonstrate that RMS-P3/RR
can directly interact with furin, and strongly suggest that the
peptide binds to the membrane-bound and soluble form of mature
furin at its active site.
RMS-P3 binding correlates with furin expression in vivo
To validate RMS-P3 binding to furin in vivo, we first tested
the tumor homing ability of phage RMS-P3/RR to RD, RD-
FUR and RD-PDX derived tumors. Phage RMS-P3/RR
showed a 2-fold increased homing to RD-FUR compared to
RD and a 45-fold increased binding compared to RD-PDX
tumors. Binding to RD-FUR cells was significantly higher than
to RD cells, and both were significantly higher than bindings to
Furin Tumor Drug Targeting
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FITC-labeled RMS-P3/RR and RMS-P3/AA peptides after
i.v. injection was evaluated in cryosections of RD xenografts
(Fig. 6). Cryosections were stained either for furin (upper
panels) or for the blood vascular markers CD31 and MECA-32
(lower panels). Around the blood vessels, strong peptide
fluorescence was observed, indicating that the peptide pene-
trated about 30 mm into the tumor. No fluorescence was
detectable after injection of the control peptide. Finally, furin
colocalized with peptide RMS-P3/RR fluorescence around the
blood vessels. The peptide accumulated in tumor cells. These
results confirm homing of peptide RMS-P3/RR to RMS
tumors in vivo and underscore binding to furin as potential
intracellular targeting mechanism.
Figure 4. RMS-P3/RR phage binding correlates with furin expression levels. (A) Binding of phage RMS-P3/RR to untransfected (MRC-5),
furin-overexpressing (MRC-FUR) and empty vector transfected MRC-5 fibroblasts (MRC-EV) was tested in vitro. Phage binding was quantified over
control T7. Results of three independent experiments 6 SD are shown. Western blot of the same samples for furin expression and PCNA as loading
control (A, lower panels) (B) Micrographs of MRC-5 fibroblasts (upper row) and MRC-5-FUR (lower row) cells incubated with 100 nM FITC-RMS-P3/RR
(green) for 1h at RT, fixed and stained with the anti-furin-antibody Mon-152 (red). Nuclei are visualized by DAPI staining (blue). Yellow indicates
overlap of the two stainings. Magnification: 40x; scale bars: 20 mm. (C) Inhibition of furin maturation in a1-PDX-transfected RD cells reduces phage
binding. Phage RMS-P3/RR binding to untransfected RD, furin-inhibited RD-PDX and empty-vector transfected RD-EV cells was determined over non-
recombinant T7 in three independent experiments (means 6 SD). Expression of the inhibitor a1-PDX was confirmed by western blotting using 100 mg
cell extract with antiserum against a1AT (C, lower panels). (D) Effect of the specific PC-inhibitor Dec-RVKR-cmk on phage RMS-P3/RR binding.
Competition was performed with increasing concentrations of Dec-RVKR-cmk and constant amounts of phage (10
9 pfu). Phage binding was
calculated over T7. RMS-P3/RR phage binding decreased with increasing concentrations of Dec-RVKR-cmk (least-squares regression, N=18, r
2=0.883,
b=217.9, p,0.0001), but binding of control phage RMS-P3/AA did not.
doi:10.1371/journal.pone.0010445.g004
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To investigate the potential of RMS-P3/RR for targeted drug
delivery, doxorubicin was coupled to RMS-P3/RR (Dox-RMS-P3/
RR). Mice with size-matched RMS xenografts were treated with
Dox-RMS-P3/RR, doxorubicin and peptide RMS-P3/RR mixed
together (Dox + RMS-P3/RR), doxorubicin alone (Dox), RMS-P3/
RR alone, and vehicle alone (PBS). Targeting caused a significant
delay in tumor growth compared to untargeted drug delivery (Fig. 7).
Tumors were significantly smaller when treated with Dox-RMS-P3/
RR than with Dox alone, Dox and peptide, peptide alone or vehicle
(student’s t-test, p,0.05). During therapy, no behavioral changes
were observed that would indicate CNS toxicity, and after the
therapy, organs were examined and no overt tissue damage was
observed, i.e. no brain, heart or nephrotoxicity (data not shown).
Hence, we conclude that targeted drug delivery by RMS-P3/RR to
furin increases the treatment efficacy for RMS tumors.
Discussion
Here, we report the isolation through phage display of a RMS
targeting peptide and the identification of the proprotein
convertase furin as its corresponding target receptor. The selected
peptide showed promising therapeutic potential for targeted drug
delivery in a pre-clinical RMS mouse model.
The majority of the phage-displayed peptides selected by a
combination of in vitro and in vivo screening contained dibasic
amino acids suggesting their importance for binding to RMS
tumors. Two phage clones, RMS-P3 (CMGTINTRTKKC) and
RMS-P6 (CMGTTNTRTKKC), differing only in one amino
acid, showed strongest binding to RMS tumor cells. RMS-P3 was
chosen for further studies because of its high affinity to RMS and
the good tumor/organ ratios in both embryonal and alveolar
histosubtypes in vivo. The corresponding synthetic RMS-P3 was
validated by competition assays and a FITC-labeled RMS-P3
revealed accumulation in endothelial and peri-endothelial tumor
cells but not in normal endothelial cells in RMS xenografts.
Moreover, the peptide was able to penetrate into the cytoplasm
and accumulate in the Golgi suggesting a possible receptor-
mediated internalization.
Through single amino acid substitutions of the phage-displayed
peptide sequence, it was possible to identify the minimal essential
motif required for binding to RMS cells as Arg-X-(Arg/Lys)(Arg/
Lys): lysines and arginines were interchangeable without loss of
affinity towards RMS cells. This allowed us to design a peptide
with decreased hydrophilic character and therefore less kidney-
prone in vivo by replacement of lysines with arginines, RMS-P3/
RR (CMGTINTRTRRC) retained the RMS targeting specificity
in vitro and in vivo.
Several lines of evidence suggest that furin, the predominant
member of the PC family, is indeed a target receptor. First,
membrane-bound furin from cell lysates of furin-overexpressing
RD cells binds to RMS-P3/RR as shown by affinity chromatog-
raphy. Same results could be obtained with the soluble
recombinant furin. Second, furin overexpression in fibroblasts
increased binding of phage RMS-P3/RR. Third, staining of furin
and FITC-RMS-P3/RR on furin-overexpressing fibroblasts evi-
denced a perfect colocalization in immunofluorescence. Fourth,
phage RMS-P3/RR preferentially homed to furin-overexpressing
RMS tumors and showed decreased binding to RMS tumors with
inhibited furin activity. Fifth, phage RMS-P3/RR binding to RD
cells was inhibited by the addition of the PC specific inhibitor Dec-
RVKR-cmk. Sixth, RMS-P3/RR inhibited furin activity in a
concentration dependent manner. Taken together, these results
validate furin as a relevant target for RMS-P3/RR binding.
We do not rule out that other PCs, in particular PC7 which is
also consistently expressed in RMS, are involved in the binding, or
that additional mechanisms contribute to tumor binding and/or
internalization. Interestingly, many of the homing peptides in the
Figure 5. RMS-P3/RR peptide binds directly to furin and
inhibits its activity. Lysates of RD-FUR cells (approximately 1 mg of
total protein, upper rows) or purified recombinant furin (250 ng; lower
rows) were loaded on a RMS-P3/RR column (A) or on the control
peptide column RMS-P3/AA (B). The columns were washed 10 times to
remove unbound furin. The loaded RMS-P3/RR-column was eluted first
with control peptide RMS-P3/AA, then with peptide RMS-P3/RR. The
RMS-P3/AA column was eluted first with RMS-P3/RR and subsequently
cross-eluted with the control peptide RMS-P3/AA. The presence of furin
in aliquots from the columns (1) after binding, (2) flow through, (3) last
wash, (4) control elution and (5) competitive elution with RMS-P3/RR (in
A) and RMS-P2/AA (in B), respectively, was detected by western
blotting. (C) Fixed amounts of recombinant furin (3.3U) were incubated
with increasing concentrations of RMS-P3/RR peptide or with control
peptide (RMS-P3/AA). Furin activity was measured with the fluorogenic
substrate Boc-RRVR-AMC at excitation 370 nm/emission 460 nm. The
results of three independent experiments 6 SD are shown.
doi:10.1371/journal.pone.0010445.g005
Furin Tumor Drug Targeting
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10445literature contain an R/KXXR/K, R/KXR/K, or R/KXR/
KR/K motif, e.g. RGR [39], LyP-1 [40], RMS-I and RMS-II
[34]. Recently, in an elegant series of works the group of Ruoslahti
showed that the presence of an exposed R/KXXR/K motif at the
C-terminus of a targeting peptide leads to cell, vascular, and tissue
penetration through binding to neuropilin-1 (NRP-1) [41,42].
Notably, this C-end rule (CendR) predicts that even internal R/
KXXR/K motives can be exposed by proteolytic cleavage. These
findings can be extended and suggest that proteolytical processing
of tumor homing (poly)peptides is an important step for specific
tumor targeting. In our system, binding of RMS-P3/RR to furin
(or PC7) and on RMS cells might be a required intermediate step,
but other molecules, such as NRP-1, might be involved in the
downstream events. In addition to that, arginine-rich peptides can
penetrate cells by various mechanisms [43], macropinocytosis
being one. A peptide (CAYHRLRRC) very similar to RMS-P3/
RR, targeting the macropinocytotic pathway, was selected by
panning on leukemia and lymphoma cells [44]. Interestingly, both
cell lines used for this study, MOLT-4 [45,46] and K562 [47]
express furin, or a protease with similar specificity. In this cellular
background, furin or a related protease might be the unidentified
receptor and play an important function in macropinocytosis.
These findings underline the potential importance of furin and
other PCs for tumor targeting, but to validate RMS-P3/RR as
tumor specific therapeutic target several points will have to be
addressed. We have observed accumulation of the RMS-P3/RR
peptide in tumors, particularly around blood vessels, where it
colocalizes with furin, implying that tumor endothelial cells and
the surrounding tissue might have increased furin expression at
their surface, and therefore we conclude that RMS-P3/RR can
target both human and mouse furin. It will be necessary to
determine the biodistribution of a radiolabeled RMS-P3/RR to
confirm the tumor specificity and accumulation and to test
whether other tissues/conditions are involved in our pre-clinical
model. Generally, furin is ubiquitously expressed and necessary for
homeostasis of normal cells, raising concerns about the clinical
translation of therapies based on activity inhibition. Furin is
overexpressed in several cancers [18,48,49], however, only
increased cell surface expression in tumors would allow specific
targeted therapies with homing molecules. There are several
examples of cellular proteins that are increased at the cell surface
in tumors [50], and are receptors for homing peptides [51,52].
Furin processing and transport to the cell surface might be
specifically increased in tumor cells, as response to increased need
to process cell matrix components required for tumor proliferation
and tissue invasion. Therefore, the cancer-specific regulation of
furin processing and transport to the cell surface needs to be
further investigated to fully understand the mechanisms underly-
ing RMS specific targeting by RMS-P3/RR and to allow
improvement of furin-based tumor targeting approaches. Our
results underline the importance of furin and PCs in tumor
progression, and the need to develop novel approaches to target
furin and PCs activity. Specific inhibitors of furin activity are being
developed and improved [53,54]. It will be important to test these
inhibitors in pre-clinical settings, to verify their biodistribution,
and better understand their clinical potential.
Peptide RMS-P3/RR conjugated with doxorubicin increased its
therapeutic efficiency in RMS xenografts compared to free
doxorubicin, and it could inhibit furin activity in vitro. The
application of a targeting peptide which simultaneously inhibits
Figure 6. FITC-RMS-P3/RR and FITC-RMS-P3/AA distribution in mice bearing RD xenografts. Peptides were injected i.v. and after
circulation the mice were perfused, tumors and control organs were removed and peptide distribution was evaluated on cryosections by
fluorescence microscopy. Depicted are overlay images (B, upper left panel) and single channel pictures. FITC-peptide stainings (green), either furin or
endothelial stainings (CD31, MECA32) in red and cell nuclei in blue (DAPI) are shown. Magnification: 40x, scale bars 50 mm.
doi:10.1371/journal.pone.0010445.g006
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therapeutic opportunities. Since doxorubicin is used as standard
compound in the second-line treatment of RMS, our results
indicate a therapeutic benefit with RMS-P3/RR as vector for a
targeted drug delivery. Furthermore, when tested on different
tumor cell lines phage RMS-P3 showed a very good binding to
breast cancer, glioblastoma and melanoma. In conclusion, this
study represents the first report on therapeutic targeting
embryonal tumors. RMS-P3/RR-mediated drug delivery through
furin might be therapeutically effective for RMS targeting and
might be considered for other tumors as well.
Materials and Methods
Ethics Statement
All the animal experiments were approved and monitored by
the Veterinary Office of the Canton of Zurich according to the
Swiss Federal Law.
Statistical analysis
Statistical analysis was performed using JMP statistical software
(v7.0.2; SAS institute inc., Cary, NC). Data are expressed as
mean6SD. Statistical significance was tested with unpaired two-
tailed Student’s t-tests, or for multiple comparisons analysis of
variance (ANOVA) with Tukey Kramer HSD posthoc tests. To
test for linear effects in time dependent experiments, we used
linear least-squares regressions or ANCOVA. The differences
were considered to be significant if P,0.05.
Cell lines and cell culture
RD (eRMS), MRC-5 (fetal lung fibroblasts), MDA-MB-231
(breast adenocarcinoma) and LoVo (colorectal adenocarcinoma)
cells were obtained from ATCC (LGC Promochem, France),
SkMC-c and SkMC-p from PromoCell (Germany). Rh4, Rh18,
Rh30 and Rh36 cells (aRMS) from P. Houghton (St. Jude
Children’s Research Hospital, Memphis, TN) and FLOH-1
(aRMS) from the Olga Hospital in Stuttgart (Germany).
U87MG (glioblastoma) and A365 (melanoma) from the Depart-
ment of Dermatology of the University Hospital Zurich (Switzer-
land). Ruch2 (eRMS, botryoid subtype) and Ruch3 (eRMS) were
established in our laboratory [55]. All cells were maintained in
high glucose DMEM supplemented with 10% fetal calf serum
(Bioconcept, Switzerland), except for LoVo cells (Ham’s F12 with
10% FCS) and myoblasts (Ham’s F10 with 15% FCS and 2.5 ng/
ml human basic fibroblast growth factor 2 (Sigma)) in 10% CO2 at
37uC. All media were from Gibco (Invitrogen, Switzerland) and
contained 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin.
Plasmids and transfections
pcDNA3.1(+) containing either full length furin (FUR) [56] or
a1-AT Portland (a1-PDX), were generous gifts of Andres JP
Klein-Szanto (Fox Chase Cancer Center, Philadelphia, PA). For
stable transfections 5610
6 RD or MRC-5 cells were electroporat-
ed with 8 mg of the vectors pcDNA3.1(+)-FUR, pcDNA3.1(+)-a1-
PDX or empty pcDNA3.1(+)-EV with the Nucleofector Kit R
(Amaxa, Germany) using the program O-017. Cells were selected
with 1 mg/ml G418 (Promega, Switzerland) in growth medium.
Phage-displayed random peptide library production and
screenings
Random peptide libraries were constructed in the lytic T7
phage as previously described [39,57]. Oligonucleotides encoding
random (NNK) cyclic peptides with the general structure CXnC
(whereas X is any amino acid and n=7 to 10) were cloned into the
T7Select 415-1 vector arms according to the manufacturer’s
instructions (Novagen, Switzerland). A stop codon was inserted
following the peptide coding sequence to avoid problems posed by
concatamers ligations into the vector arms. The initial library
diversity was evaluated to be 10
8.
Negative selection: 10
6 normal myoblasts (panning I) or
fibroblasts (panning II) were detached with 2.5 mM EDTA-PBS
and reconstituted in DMEM/1%BSA before overnight incubation
with 10
9 pfu of the phage library in 1 ml DMEM/1%BSA at 4uC.
After cell sedimentation, phage were rescued from the supernatant
by amplification in the E.coli strain BLT5403 (Novagen) and used
for biopanning.
In vitro selection: 10
6 RD cells were detached and,
reconstituted as described above. Cells were incubated with 10
9
pfu of the precleared library for 2 hours at 4uC under rotation.
Unbound phages were removed by four washing steps with
DMEM/1%BSA and cells were treated for 30 minutes with 1%
NP-40 on ice. Bound phage were rescued and amplified. Phage
enrichment was calculated after every round of panning over
binding of non-recombinant T7 control phage.
In vivo selection: Phage (10
10 pfu) from in vitro biopannings
were tail vein injected into mice bearing size-matched RMS
tumors (500 mm
3) as described in [57].
Mutagenesis of phage displayed peptide sequences
(Ala-scan)
Each codon of RMS-P3 was replaced by the alanine codon
GCT. Oligonucleotides (Microsynth, Switzerland) were designed
to have EcoRI and HinDIII sites and cloned into the T7Select
415-1 vector arms. Packaging and amplification in E.coli
Figure 7. Targeted drug delivery with Dox-RMS-P3/RR in NOD/
SCID mice bearing RD xenografts. Five groups of 6 mice were
treated when tumors reached 60 mm
3 in size. Treatment consisted of
weekly tail vein injections for 30 days. Mice were treated with 10 mg/
week of free doxorubicin (n), 10 mg doxorubicin equivalent/week of
doxorubicin-coupled RMS-P3/RR peptide (&), with molar equivalent of
free peptide RMS-P3/RR (N), 10 mg/week free doxorubicin plus molar
equivalent of free peptide RMS-P3/RR (.) or with vehicle alone
(PBS, %). Treatment efficacy was best for Dox-RMS-P3/RR, significantly
better than for Dox alone or other treatments. Pairwise student’s t-tests
on day 30, Dox-RMS-P3/RR vs. Dox alone: p=0.042, Dox-RMS-P3/RR vs.
peptide RMS-P3/RR: p=0.0004, Dox-RMS-P3/RR vs. placebo: p,0.0001.
doi:10.1371/journal.pone.0010445.g007
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(Novagen). Single phage clones were verified by DNA sequencing.
Affimetrix gene expression profiling
mRNA expression levels of different proprotein convertases
were evaluated from previously generated gene expression data of
30 RMS biopsy samples [58] and from newly acquired data of 9
RMS cell lines and 4 myoblasts cultures.
Quantitative Real time PCR
Total RNA was extracted with the RNeasy Kit (Quiagen,
Switzerland). Following DNase treatment, samples (1 mg) were
reverse-transcribed with Oligo(dT) primers using the Omniscript
Reverse Transcription Kit (Qiagen). qRT-PCR detection of furin
and the house keeping gene GAPDH was performed with assay-
on-demand Hs00965485_g1 and Hs99999905_m1, respectively
(Applied Biosystems) and normalized to GAPDH. Experiments
were performed in triplicates. Mean values and standard
deviations were calculated based on the results of three biological
replicates.
Western blotting
10
7 cells were denatured in RIPA buffer supplemented with 1
mM PMSF and Roche Complete Protease inhibitor (Roche,
Switzerland) for 30 minutes on ice. Total cell extract (100 mg) was
separated on 4–12% NuPAGE Bis-Tris gels (Invitrogen) and
blotted on nitrocellulose membranes (Schleicher & Schuell,
Germany). Blots were blocked with 3% BSA, incubated with the
first antibody overnight at 4uC and with the corresponding HRP-
conjugated secondary antibody for 1 hour at RT. Enhanced
chemiluminescence detection system (SuperSignal West Femto,
Pierce, Perbio Science, Switzerland) was used for detection of furin
(MON-152, 1:750; Alexis Corporation, Switzerland). Anti-a1-
Antitrypsin antibody produced in rabbit (A0409; 1:1000, Sigma-
Aldrich), PCNA (1:1000, Bioscience, Switzerland).
Synthesis of peptides
The cyclic peptides CSPNNTRRPNKC (RMS-Pctrl),
CMGTINTRTKKC (RMS-P3), CMGTINTRTRRC (RMS-
P3/RR) and CMGTINTATAAC (RMS-P3/AA) were synthe-
sized using standard FMOC chemistry in a solid-phase synthesizer
by Eurogentec (Belgium). Fluorescein (FITC)-conjugated peptides
contained a spacer of two glycines at the amino-terminus of the
cysteine. Doxorubicin-succinyl-GG-CMGTINTRTRRC (Dox-
RSM-P3/RR) was synthesized by BiomerTechnology (Hayward,
CA) in a purity of .90%.
Competition assays
10
6 RD cells were detached (2.5 mM EDTA-PBS) and
reconstituted (DMEM/1% BSA). Cells were preincubated with
100 ml of peptides (RMS-P3 or RMS-Pctrl) or general PC inhibitor
decanoyl-Arg-Val-Lys-Arg-chloromethylketone (Dec-RVKR-cmk,
Calbiochem, Switzerland) for 30 minutes. Phages (10
9 pfu) were
added for 1 hour at RT under continuous rotation. Cells were
washed four times with DMEM/1% BSA; titer of bound phage
was determined by titration with BLT5403 and calculated over
non-recombinant T7.
Furin activity
The enzymatic activity of furin was determined by the cleavage
of the fluorogenic substrate Boc-RRVR-AMC (Alexis biochemi-
cals) in presence or absence of peptides. Human recombinant furin
(3.3U for reaction; Alexis biochemicals) was preincubated for 15
minutes at RT with the peptide RMS-P3/RR or the peptide
RMS-P3/AA as negative control at increasing concentrations. For
each assay, the same concentration of substrate (100 mM) was
added to a solution containing 50 mM Tris HCl with 1 mM
CaCl2 (pH 7) in a total volume of 100 ml. The reaction was
followed for 1h while measuring the fluorescence every 10 minutes
in a spectrofluorometer at excitation 370 nm/emission 460 nm.
RMS-P3/RR affinity chromatography
RMS-P3/RR or control peptide RMS-P3/AA were dissolved in
0.2 M phosphate buffer pH 7.2 to 1 mg/ml and covalently linked
to NHS-activated sepharose matrix SpinTrapTM (GE Healthcare,
Amersham Biosciences, Switzerland). Free residual active groups
were blocked according to manufacturer’s instruction. Peptide
columns were incubated either with 400 ml RD-FUR cell lysate in
non-denaturating RIPA buffer (approximately 1 mg of total
protein) or with 5U of recombinant human furin (approximately
250 ng of pure enzyme, Alexis Corporation) in 100 ml TBS
(pH 7.5) overnight at 4uC under continuous rotation. After
washings with 10 column volumes of TBS, each peptide (2 mg/
ml in TBS) was applied to the column for 2 hours at 4uC.
Competitive elution from the RMS-P3/RR column was per-
formed first with the control peptide RMS-P3/AA then with
RMS-P3/RR, each in two volumes of column buffer. The column
with the control peptide RMS-P3/AA was eluted first with RMS-
P3/RR followed by an elution with RMS-P3/AA.
Fluorescence microscopy
5610
4 cells grown in chamber slides (BD Biosciences,
Switzerland) were incubated for 1 hour at 37uC either with
100 nM FITC-RMS-P3 or FITC-RMS-Pctrl. Then, cells were
washed with Dulbecco’s PBS (Amimed, Bioconcept, Switzerland),
fixed with 4% PFA for 15 minutes and permeabilized with 1%
Triton X-100 in PBS for 15 minutes at RT and stained with Mon-
152 (1:100, Alexis Corporation). Polyclonal anti-giantin antibody
(1:1000, Abcam, Cambridge, UK). AlexaFluor594-labeled IgG
antibodies (Invitrogen) were diluted 1:300 in PBS/0.1%BSA. Cells
were stained with 49,6-diamidino-2-phanylindole (DAPI), washed
twice with PBS and mounted with Vectashield Mounting medium
(Reactolab SA, Switzerland). All images were obtained on an
Axioskop 2 mot plus Fluorescent microscope (Carl Zeiss Visions,
Switzerland).
Animal models
CD1-Nu/nu mice (4 to 6 weeks old, Charles River, Germany)
were used for the in vivo screening, and 6 weeks old NOD/SCID
IL2R c-/- mice were used for all other studies. RMS cells (5610
6
in 150 ml HBSS) were injected subcutaneously into the dorsolat-
eral flank of the mice. Both diameters (d) of the spherical tumors
were measured twice weekly and the volume was calculated with
the general formula V=(4/3) pr
3, whereby r=(d1+d2)/4. Prior to
the experiment, mice were anesthetized with 0.015 ml/g avertin
by i.p. injection. 1 mg/ml of FITC-peptide in 250 ml PBS was
injected by tail vein injection into mice bearing tumors 150 mm
3
in size. After 10 minutes circulation, mice were perfused, tumor
and control organs were dissected and frozen in O.C.T.
embedding medium (Leica Microsystems, Germany). 10 mm
cryosections were washed with PBS, fixed for 15 minutes in ice-
cold methanol and air-dried. Endothelial stainings were performed
using rat monoclonal antibodies against mouse markers CD31 and
MECA-32, both at the dilution of 1:50 (BD biosciences,
Switzerland). A rabbit polyclonal anti-furin-antibody (Abcam)
was used at a dilution of 1:1500. All corresponding secondary
antibodies were AlexaFluor594-labeled IgGs (1:300, Invitrogen).
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bearing mice
Mice with size-matched tumors (,60 mm
3) were randomized
into five groups and injected once per week for 4 consecutive
weeks. The therapeutic groups received weekly either 10 mg
doxorubicin or 10 mg equivalent of Dox-RMS-P3/RR conjugate.
Control groups received either a mixture of 10 mg free
doxorubicin and peptide RMS-P3/RR, an equimolar solution of
peptide RMS-P-3/RR alone or PBS alone. Concentrations were
confirmed by measuring the absorbance of conjugated doxorubi-
cin at 490 nm. A calibration curve of doxorubicin was used for
calculation of equivalent Dox-RMS-P3/RR concentrations. Mice
were monitored for weight and tumor growth for 30 days.
Supporting Information
Figure S1 Phage selection and validation on RMS cells in vivo
and in vitro. (A) Biopanning on RD cells in vitro after negative
selection on myoblasts (panning I) and (B) fibroblasts (panning II).
Enrichment was calculated over non-recombinant phage T7. (C)
In vivo selection in Rh4 xenografts. Phages from in vitro selection
before enrichment were pooled and used for in vivo selection in
Rh4 xenografts. Phages were injected in the tail vein and after 10
min circulation unbound phages were washed by perfusion. Phage
binding to tumors and control organs was calculated over non-
recombinant phage T7. (D) RMS-P3 and RMS-P6 phage
distribution in Rh4 xenografts. Homing of phages in mouse
xenografts bearing Rh4 tumors was determined and compared to
control organs. Binding was normalized over phage T7 and tissue
weight. Mean values of three independent experiments are shown.
Numerical values for tumor to organ ratios are indicated above the
bars. (E) Quantification of binding of RMS-P3 phage to a panel of
tumor cell lines: RMS (RD, Rh30, Rh4), breast tumor (MDA-MB
231), glioblastoma (U87MG), melanoma (A365); and normal
myoblasts (SkMC-c) and fibroblast cells (MRC-5). Mean values 6
SD of three independent experiments are depicted.
Found at: doi:10.1371/journal.pone.0010445.s001 (0.55 MB TIF)
Figure S2 Subcellular localization of FITC-RMS-P3 peptide. (A,
B) FITC-RMS-P3/RR cell surface and intracellular localization.
RD cells were incubated with 100 nM FITC-RMS-P3 peptide in
vitro for 30 min at 4uC( A )o r3 7 uC (B), respectively. Fixed cells were
stained with undiluted 5.1H11 hybridoma supernatant against the
human muscle-specific cell surface antigen N-CAM (red). A
secondary rabbit anti-mouse Cy3 antibody (1:300, Invitrogen) was
used for detection. Examination under the confocal laser scan
microscope revealed a strong incorporation of the peptide (green) at
37uC (B), but also a distinguishable internalization at 4uC( A ) .
Interestingly, surface localization, as indicated by colocalization
with N-CAM staining, was visible only at 4uC suggesting complete
internalization of FITC-RMS-P3 peptide at 37uC. Cell nuclei were
visualized with DAPI. Nuclei are indicated in grey. Magnification:
63x, scale bars: 20 mm. Laser scan images were acquired on a Leica
TCS/SP2 confocal microscope (Leica, Wetzlar, Germany) with a
63x water immersion objective, equipped with both argon ion
(488 nm, for fluorescein excitation, PMT window 498-540 nm) and
HeNe laser. The 543 nm HeNe laser was used to excite Cy3 (PMT
window: 553-600 nm). For the double labeling, images from two
different channels were collected separately in every focal plane.
Between 5 and 15 sections in the z-axis (xy-mode) or y-axis (xz-
mode) were acquired, and maximum projections of the sections
encompassing the nucleus were performed. (B, C) Laser confocal
microscopy of FITC-RMS-P3 in tumors. FITC-labeled peptide
(150 mg) was injected i.v. in mice bearing RD xenografts and
allowed to circulate for 10 min. After perfusion, tumors and control
organs were removed and peptide distribution was evaluated on
cryosections (10 mm) by laser scan confocal microscopy. RD tumor
sections show FITC-RMS-P3 (green) and cell nuclei visualized with
DAPI (white). FITC-RMS-P3 internalization in tumor cells is
visible. Magnification: 63x, scale bars: 20 mm. Laser scan images
were acquired on a Leica TCS/SP2 confocal microscope (Leica,
Wetzlar, Germany) with a water immersion objective and equipped
with both argon ion (PMT window: 488-540 nm) and HeNe laser
(PMT window: 553-600 nm). Images were collected separately in
every focal plane. 12 sections in the z-axis (xy-mode) or y-axis (xz-
mode) were acquired, and maximum projections of the sections
encompassing the nucleus were performed.
Found at: doi:10.1371/journal.pone.0010445.s002 (3.96 MB TIF)
Figure S3 Phage RMS-P3/RR distribution in RMS xenografts.
Phage distribution in mice bearing xenografts was assessed after
tail vein injection and circulation. After perfusion, tumors and
control organs were removed. Phage were rescued and normalized
over weight of tissue. Phage RMS-P3/RR showed a 2-fold
increased homing to RD-FUR compared to RD and a 45-fold
increased binding compared to RD-PDX tumors. Binding to RD-
FUR cells was significantly higher than to RD cells, and both were
significantly higher than bindings to any other organ. (One-way
ANOVA, Tukey Kramer HSD, p,0.05). Further, binding to
RMS-FUR tumor was higher than to muscle (27-fold), brain (17-
fold), intestines (6-fold) and kidney (22-fold). Binding of control
phage RMS-P3/AA was higher to control organs than to tumors.
Indicated are means 6 SD of three independent experiments.
Found at: doi:10.1371/journal.pone.0010445.s003 (0.81 MB TIF)
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